Open AccessAntibiotic Resistance Patterns in Invasive Group B Streptococcal Isolates
Author(s) -
Mei L. Castor,
Cynthia G. Whitney,
Kathryn ComoSabetti,
Richard R. Facklam,
Patricia Ferrieri,
Joanne M. Bartkus,
Billie A. Juni,
Paul R. Cieslak,
Monica M. Farley,
Nellie B. Dumas,
Stephanie J. Schrag,
Ruth Lynfield
Publication year - 2008
Publication title -
infectious diseases in obstetrics and gynecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.656
H-Index - 48
eISSN - 1098-0997
pISSN - 1064-7449
DOI - 10.1155/2008/727505
Subject(s) - clindamycin , erythromycin , penicillin , cefazolin , cefotaxime , ampicillin , medicine , microbiology and biotechnology , antibiotics , population , antibiotic resistance , amp resistance , biology , environmental health
Antibiotics are used for both group B streptococcal (GBS) prevention and treatment. Active population-based surveillance for invasive GBS disease was conducted in four states during 1996–2003. Of 3813 case-isolates, 91.0% (3471) were serotyped, 77.1% (2937) had susceptibility testing, and 46.6% (3471) had both. All were sensitive to penicillin, ampicillin, cefazolin, cefotaxime, and vancomycin. Clindamycin and erythromycin resistance was 12.7% and 25.6%, respectively, and associated with serotype V ( P < .001). Clindamycin resistance increased from 10.5% to 15.0% ( X 2 for trend 12.70; P < .001); inducible clindamycin resistance was associated with the erm genotype. Erythromycin resistance increased from 15.8% to 32.8% ( X 2 for trend 55.46; P < .001). While GBS remains susceptible to beta-lactams, resistance to alternative agents such as erythromycin and clindamycin is an increasing concern.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom